Close Menu

NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its second quarter revenues rose 4 percent, driven in part by strong growth in automated sample-to-answer molecular products sales.

For the three months ended June 30, the firm reported revenues of $79.6 million, up from $76.5 million a year ago, and in line with the consensus Wall Street estimate.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.